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Customized Order-Entry Sets Can Prevent
Antiretroviral Prescribing Errors: A Novel Opportunity
For Antimicrobial Stewardship
Yi Guo, PharmD; Philip Chung, PharmD, BCPS; Car yn Weiss, ANP;
Keith Veltri, PharmD; and Grace Y. Minamoto, MD

ABSTRACT

Background: Patients with human immunodeficiency virus
(HIV) infection on antiretroviral (ARV) therapy are at increased
risk for medication errors during transitions of care between
the outpatient and inpatient settings. This can lead to treatment failure or toxicity. Previous studies have emphasized
the prevalence of medication errors in such patients, but few
have reported initiatives to prevent errors from occurring.
Methods: The study was conducted in a 1,400-bed health
care center with a state-designated Acquired Immunodeficiency
Syndrome (AIDS) Center in the Bronx, New York. The antimicrobial stewardship team and HIV specialists developed
customized order-entry sets (COES) to guide ARV prescribing and retrospectively reviewed their effect on error rates of
initial ARV orders for inpatients before reconciliation. Patient
records were reviewed in six-month periods before and after
intervention. The student’s t-test or Mann–Whitney U test was
used to compare continuous variables; chi-square or Fisher’s
exact test was used for categorical variables.
Results: A total of 723 and 661 admissions were included in
the pre-intervention and post-intervention periods, respectively.
Overall, error rates decreased by 35% (38.0% to 24.8%, P < 0.01)
with COES. Wrong doses and drug interactions decreased by
more than 40% (P < 0.005). Error reductions were observed
in protease inhibitor (PI)-based (43.6% versus 28.7%, P < 0.01)
and non–PI-based (38.0% versus 24.4%, P = 0.02) regimens with
COES. A shift in predominant drug-class errors was observed
as there was a trend toward increased usage of non-PI regimens
post-intervention. Admission in the pre-intervention period
(adjusted odds ratio [AOR], 1.79; 95% confidence interval
[CI], 1.39–2.31) and use of PI-based regimens (AOR, 2.03;
95% CI, 1.53–2.70) remained significantly associated with ARV
prescribing errors after controlling for confounding factors.
Conclusion: Detailed COES improved ARV prescribing
habits, reduced the potential for prescribing incorrect regimens, and can prove useful and cost-effective where HIVspecific medication reconciliation is unavailable.
Dr. Guo and Dr. Chung are Clinical Pharmacy Managers in the
Department of Pharmacy and Assistant Professors in the Division
of Infectious Diseases at Montefiore Medical Center and the Albert
Einstein College of Medicine in Bronx, New York. Caryn Weiss is a
Nurse Practitioner in the Department of Medicine, Division of Infectious Diseases, at Montefiore and Einstein. Dr. Veltri is a Clinical
Pharmacy Manager in the Department of Pharmacy at Montefiore
and Einstein and Associate Professor at Touro College of Pharmacy
in New York, New York. Dr. Minamoto is an Attending Physician
and Associate Professor in the Department of Medicine, Division of
Infectious Diseases, at Montefiore and Einstein.
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INTRODUCTION

At least 1.5 million preventable adverse drug events occur
each year in the U.S. because of medication errors.1 Several
studies have found that many of these occur during the transition of care between the outpatient and inpatient settings.2–5
Individuals infected with human immunodeficiency virus
(HIV) are particularly vulnerable during periods of transition.6
Prescribing errors involving patients receiving antiretroviral
(ARV) therapy are significantly higher than rates reported
in individuals without HIV infection.3,4,7 It is estimated that
more than 84% of hospitalized patients with HIV infection
may experience an ARV-related error.7 The etiology of these
errors is often multifactorial and includes lack of provider
knowledge or familiarity with the disease state,1 complexity
of regimens, and frequent regimen revisions. The widespread
use of potent combination ARV therapy has reduced hospitalizations for opportunistic infections and other HIV-related
conditions,8 has increased life expectancy for those with HIV
infections, and has resulted in an increase in hospitalizations
for other comorbid medical problems. Increasingly, medical
staff members without formal training in HIV management or
infectious diseases have been providing inpatient care to HIV
patients. In addition, comorbidities may increase the potential
for clinically significant drug interactions and polypharmacy.9
ARV prescribing errors may lead to treatment failure, development of resistance, and suboptimal dosing or drug toxicity. It is
therefore crucial that these patients’ therapies are appropriately
continued during their hospitalizations.
Many studies have emphasized the prevalence of medication errors in hospitalized patients with HIV infection.1–4,7,10–26
Frequently cited errors include medication omission, dosing
errors, incorrect scheduling, and drug interactions; errors are
associated with all major drug classes, including nucleos(t)ide
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
In our institution, monthly in-service training sessions for
house staff, physician assistants, and pharmacists were conducted along with the provision of reference materials. An ARV
medication chart was developed, which included routine doses;
interactions of commonly used medications as well as other
ARV medications; weight and renal dosing recommendations;
and contraindications for use of other medications. Pop-up alerts
in the computerized prescriber order-entry system (CPOE;
Disclosure: The authors report no commercial or financial interests
in regard to this article.
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Figure 1 Examples of Customized Order-Entry Sets
A

B

Customized order-entry sets within the computerized prescriber order-entry system offer guidance on drug interactions and
dosage for specific settings—in these examples, when prescribing atazanavir (A) and on dose adjustment for renal insufficiency
for prescribing coformulated emtricitabine and tenofovir (B).
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CareCast version 3.04) were added to remind ordering prescribers of the need for complete regimens, deferring ordering
until correct regimens could be confirmed. ARV orders are
routinely reviewed by the AIDS Center nurse practitioner and
hospital pharmacy staff members, who alert prescribing staff
to the need for order corrections. However, errors for ARV
orders can still occur.
The antimicrobial stewardship team and HIV specialists
determined that an enhanced system would be necessary
to prevent ARV errors before they actually occur. In 2011,
customized order-entry sets (COES) for ARV medications
were developed and implemented in our institution to further
prevent ARV-related errors prospectively in addition to CPOE
and periodic educational in-service sessions (Figure 1). CPOE
with COES prevents prescribers from ordering incomplete
regimens, provides dosing guidance based on renal function
and concomitant drug therapy, and flags contraindicated drug
interactions prior to the commission of potential ARV errors in
real time. The objective of this study was to evaluate the effect
of CPOE with COES on error rates of initial ARV orders for
inpatients with HIV infection prior to reconciliation of orders
by HIV clinical specialists and pharmacists.

METHODS

Study Population and Setting

Our institution is a 1,400-bed academic health care system in
the Bronx, New York, with more than 90,000 inpatient admissions annually, of which more than 1,700 are for HIV-infected
individuals. In a Bronx population of nearly 1.4 million people,
more than 23,000 are living with HIV.27 The system is one of
the few regional hospitals with a dedicated team consisting of a
medical director, a nurse practitioner, and social workers who
monitor the care of any patient admitted with the diagnosis
of HIV. Our institution does not maintain a dedicated HIV
patient-care unit; rather, patients are cared for throughout the
hospital on units appropriate to their medical or surgical needs.
The study was approved by the Montefiore Medical Center/
Albert Einstein College of Medicine institutional review board.

Data Collection

The time frames reviewed were September 2010 to February
2011 (a six-month period before implementation of the COES
in August 2011) and September 2011 to February 2012. The
charts of all hospitalized adult patients (older than 18 years
of age) for whom ARVs were ordered were retrospectively
reviewed. Patients without HIV infection who were prescribed
lamivudine or tenofovir for hepatitis B infection were excluded.
Patient characteristics obtained included age, sex, race, medical
service, HIV viral load, CD4 cell count, creatinine clearance
(estimated based on the Cockcroft–Gault equation), ARV regimens initially prescribed, and medications with the potential
for drug–drug interactions. The CD4 cell counts and HIV viral
load results used in this study were those values within six
months of and closest to the dates of admission.
ARV regimens were classified as consisting of a singleformulation preparation (e.g., emtricitabine/tenofovir/efavirenz
[Atripla, Gilead Sciences]), protease inhibitor (PI)-based, or
non–PI-based. Prescribing errors were categorized as incomplete regimens, incorrect ARV drug, incorrect dosing of at

least one ARV drug, incorrect scheduling frequency, incorrect
dosing of at least one drug for renal insufficiency, and regimens
that included an agent with interaction potential with another
prescribed drug.
Prescribing errors were enumerated differently based on
analysis parameters. For determination of admissions with any
ARV errors, one or more prescribing error(s) within an ARV
regimen was tallied as one admission with ARV prescribing
error(s). For determination of a specific type of error within
an ARV regimen, one or more error(s) of a specific type (e.g.,
wrong dose) was counted as one type-specific error against a
regimen. Finally, for determination of a specific type of error
based on drug classes, each error was tallied individually.

Analysis

Chi-square and Fisher’s exact tests as appropriate were
used to assess associations between categorical variables; the
Mann–Whitney test was used to compare continuous variables
among groups. Multivariate logistic regression analysis was
performed to determine variables independently associated
with ARV prescribing errors. Variables with a P value of less
than 0.20 on univariate analysis, intervention period, and
internal medicine as admitting service were included in the
logistic regression model. A two-tailed P value of less than 0.05
represented statistical significance for all statistical comparisons. Statistical analyses were performed using SAS version
9.4 (SAS Institute Inc., Cary, North Carolina).

RESULTS

A total of 1,486 and 1,316 admissions involved patients
with a diagnosis of HIV during the pre-intervention and postintervention periods, respectively. Among these hospitalizations, ARVs were prescribed in 723 admissions involving 519
patients in the pre-intervention period and 661 admissions
involving 489 patients in the post-intervention period. Patient
demographics for the two study periods were comparable
(Table 1). The median age of the study population was approximately 50 years; approximately 46% of the patients were female.
Nearly three-quarters of the study population identified themselves as either African-American or multiracial. The majority
of study patients (more than 70%) were admitted to an internal
medicine service, while relatively fewer patients were admitted
to a surgical service or critical-care unit. Forty-nine percent and
54% of patients had undetectable viral loads (40 copies/mL or
less) during the pre-intervention and post-intervention periods,
respectively. CD4 counts were more than 200 cells/mcL in
approximately 60% of patients and more than 500 cells/mcL
in more than 25% of patients. Types of regimens prescribed
during hospital admissions in the pre-intervention and postintervention periods were similar; PI-based regimens were
the most commonly prescribed during both study periods
(Table 1, Figure 2).
Prior to the initiation of COES, ARV prescribing errors of any
type were observed in 275 admissions (38.0%). Use of COES,
along with prescriber education, reduced ARV prescribing
errors in 164 admissions (24.8%), representing an error reduction rate of 34.7% (P < 0.01). The most commonly observed
errors were use of an incorrect ARV dose (13.8%) and drug
interaction with an ARV (10.2%) during the pre-intervention
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When stratified by regimen type, significant error reductions in PI-based regimens
(43.6% versus 28.7%, P < 0.01) and non–
PI-based regimens (38.0% versus 24.4%,
P = 0.02) were observed with use of COES.
Characteristics
Pre-Intervention Post-Intervention P Values
A greater than 50% reduction in single-pill
Period (n = 723)
Period (n = 661)
combination ARV errors was also observed,
Median age, years (range)
51 (18–88)
52 (22–93)
0.78
albeit not statistically significant due to the
Female, n (%)
333 (46.1)
315 (47.7)
0.55
small number of patients on this type of
therapy (8.6% versus 3.9%, P = 0.35).
Race, n (%)
When stratified by drug class, a change
African-American
318 (44.0)
333 (50.4)
in the composition of prescribing errors was
observed between the two study periods
Multiracial
218 (30.2)
178 (26.9)
0.17
(Figure 4). Prior to the introduction of COES,
Hispanic
63 (8.7)
50 (7.6)
PI errors were the most common among the
Caucasian
62 (8.6)
56 (8.5)
five ARV classes, accounting for 49.8% of 319
errors. Errors involving NRTIs were the
Other
62 (8.6)
44 (6.7)
next most common at 40.7%. With the use of
Admitting service, n (%)
COES, NRTI prescribing errors became the
Internal medicine
528 (73.0)
486 (73.5)
most common (53.9% of 167 errors), followed
by PI errors (34.1%). The percentage of
Surgery
50 (6.9)
43 (6.5)
0.32
errors involving the remaining three classes
Critical care
2 (0.3)
7 (1.1)
of ARVs was not significantly different with
or without implementation of COES.
Other*
143 (19.8)
125 (18.9)
Closer examination of different types of
Median length of stay, days (range)
5 (1–135)
5 (1–126)
0.41
errors within each drug class revealed wrong
Viral load > 40 copies/mL, n (%)
312/616 (50.7)
272/592 (46.0)
0.10
dose/frequency and drug-interaction errors
with protease inhibitors were significantly
CD4 count < 200 cells/mcL, n (%)
257/671 (38.3)
230/623 (36.9)
0.61
reduced after the introduction of COES
PI-based ARV regimen
493 (68.2)
428 (64.8)
0.10
(Table 2). Errors related to NRTI dose
* “Other” includes services such as family medicine, oncology, etc.
adjustment due to renal dysfunction also
ARV = antiretroviral; PI = protease inhibitor
significantly declined. Prescribing errors
associated with NNRTIs, chemokine (C-C
motif) receptor 5 (CCR5) inhibitors, and integrase inhibitors
Figure 2 Types of Regimens Prescribed During
did not change significantly between the two study periods,
Hospital Admission in the Pre-Intervention (A) and
most likely because of the small number of patients using
Post-Intervention (B) Periods
these drug classes.
In addition to intervention period and internal medicine
B
A
as admitting service, the variables of race, viral load greater
Single Single pill ARV
pill ARV
than 40 copies/mL, and ARV regimen (all with P values of
11.6%
12.9%
less than 0.20 on univariate analysis, Table 1) were included
in the logistic regression analysis model. After controlling for
potential confounders, pre-intervention period (adjusted odds
ratio [AOR], 1.79; 95% confidence interval [CI], 1.39–2.31;
P < 0.01) and PI-based ARV regimen (AOR, 2.03; 95% CI,
Non–PI-based
Non–PI-based
1.53–2.70, P < 0.01) remained significantly associated with
18.9%
23.6%
PI-based
PI-based
ARV prescribing errors (Table 3).
64.8%
68.2%

Table 1 Demographics of Hospitalized Patients With Human
Immunodeficiency Virus Infection on Antiretroviral Therapy
During the Pre-Intervention and Post-Intervention Periods

DISCUSSION
ARV = antiretroviral therapy; PI = protease inhibitor

period. With the use of COES, reductions of 49% in wrong
dose and 43% in drug-interaction errors were observed. COES,
however, did not significantly reduce errors of prescribing
the incorrect ARV (1.8% pre-intervention versus 1.2% postintervention, P = 0.39) or wrong frequency (7.6% versus 6.1%,
P = 0.29). Figure 3 further details changes in error rates
between the pre-intervention and post-intervention periods.
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It is becoming increasingly difficult for physicians to stay
abreast of changes in HIV drug management. The expanding
number of ARVs approved by the Food and Drug Administration
and the potential number of drug combinations, as well as
frequent changes in clinical practice guidelines, can be overwhelming to medical providers. Improved measures to assist
prescribers with error prevention are much needed.
This study demonstrated that ARV prescribing errors in an
inpatient setting can be substantially reduced by CPOE with
COES. More importantly, COES prevented a large number of

Customized Order-Entry Sets Can Prevent Antiretroviral Prescribing Errors
Figure 3 Change in Error Rates Between Pre-Intervention and Post-Intervention Periods
Pre-Intervention
Post-Intervention

50
45

Pre-Intervention

30

45

24.8

25

38.0

40

20
15

P = 0.005

10

6.9
3.5

5
0

Any error

Incomplete
regimen

P < 0.001

35
30

24.8

25
20 1.8

15Incorrect drug
10

B

A

PI
49.8%

7.0

7.6

P = 0.002

10.2

9.4
6.1

5.3

Wrong
frequency

Not renally
dosed

5.8

1.2

Figure 4 Compositions of ARV Errors During the
Pre-Intervention (A) and Post-Intervention (B) Periods
Integrase inhibitor
3.2%
CCR5s
NNRTIs
0.6%
5.7%

P = 0.004

13.8

these errors prior to patients receiving their first ARV doses
5 is the largest
during hospitalization. To our knowledge, this
and only study to date in a region of high HIV prevalence that
0 on the reducreviews the effects of such an ordering system
tion of potential medication errors before they occur, rather
than rectifying mistakes after they have transpired. The multi
disciplinary collaboration between the departments of infectious diseases, pharmacy, and information technology made the
CPOE with COES possible for our institution. We constructed
a COES for each ARV that is simple in design (Figure 1) and
can be easily reproduced and implemented by most small or
large institutions with CPOE. These ordering screens can be
especially important for reducing ARV errors if the institution

NRTIs
40.7%

Post-Intervention

50

35

Percent of admissions

Percent of admissions

40

P < 0.001
38.0

Integrase inhibitor
CCR5s
4.8%
3.0%
NNRTIs
4.2%

PI
34.1%
NRTIs
53.9%

CCR5 = chemokine (C-C motif) receptor 5 inhibitors; PI = protease inhibitor;
NNRTIs = non-nucleoside reverse transcriptase inhibitors; NRTIs = nucleos(t)ide
reverse transcriptase inhibitors

Wrong dose

6.9

13.8

Drug
interactions

7.6

7.0

does not have
3.5 designated pharmacists or medical staff trained
in infectious diseases1.8to review
1.2 ART on a daily basis.
Overall, COES reduced errors of any type by 34.7%, primarily
due to reductions in PI and renal dosing errors. Error rates
were significantly reduced for incomplete regimens, incorrect
dose, and drug interactions. There was no significant impact
on incorrect ARV choice and on dosing frequency, but a trend
toward reduction was observed. The lack of impact on incorrect
ARV choice is likely multifactorial in etiology. COES cannot
distinguish between the choices of protease inhibitors (e.g.,
atazanavir [Reyataz, Bristol-Myers Squibb] versus darunavir [Prezista, Janssen]), NRTIs (e.g., emtricitabine/tenofovir [Truvada, Gilead Sciences] versus lamivudine/abacavir
[Epzicom, ViiV Healthcare]), or NNRTIs (e.g., nevirapine
[Viramune, Boehringer Ingelheim] versus efavirenz [Sustiva,
Bristol-Myers Squibb]).
In almost all cases, ARV regimens of hospitalized patients
are initiated by outside HIV care providers. The occasional
lack of access to the correct ARV regimen, especially for those
patients whose records are not part of the hospital’s medical
record system, poses challenges for inpatient house staff.
Prompt communication with the primary HIV care provider
will help to reduce the number of errors for ARV choice and
address the inability of COES to make intra-class distinctions. Incorrect creatinine clearance calculations may have
contributed to incorrect dosing frequency errors. Further
education is needed on using the Cockcroft–Gault equation
for creatinine clearance calculations in order to reduce error
in dosing frequency.
Error rates for PI-based and non–PI-based regimens similarly improved after the introduction of COES (pre-intervention: PI-based, 43.6%, non–PI-based, 38%; post-intervention:
PI-based, 28.7%, non–PI-based, 24.4%). A number of studies4,21–23
have found that the ordering of PIs is more likely to be associ-
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prescribing of these formulations occurred in
our population precisely for this reason. In a
prospective French study involving HIV seroCharacteristics
Pre-Intervention Post-Intervention
%
P Values
positive hemodialysis patients, underdosing
Period (n = 723)a Period (n = 661)a
Change
and overdosing errors occurred among 59%
of ARV medications prescribed.18
NRTI errors
A variety of interventions to reduce ARV
Wrong dose
34 (4.7)
26 (3.9)
−17.0
0.51
prescribing errors have been investigated.
Several studies are based primarily on the
Wrong frequency
21 (2.9)
27 (4.1)
+41.4
0.31
inter vention by the pharmacy, in which
Not renally dosed
68 (9.4)
35 (5.3)
−43.6
< 0.01 b
inpatient pharmacy staff members reconcile
Drug interaction
6 (0.8)
2 (0.3)
−62.5
0.29
outpatient regimens with inpatient orders
and often consult the patients’ medical care
NNRTI errors
providers or families.3,9,11,21,23 Other studies
Wrong dose
9 (1.2)
2 (0.3)
−75.0
0.07
have used a multidisciplinary approach that
Wrong frequency
4 (0.6)
4 (0.6)
0.0
1.00
typically included a combination of computerized alerts, physician and pharmacy
Drug interaction
5 (0.7)
1 (0.2)
−71.4
0.22
review, and educational measures. Yehia
PI errors
et al. used such an approach with a CPOE
with drug–drug interaction alerts and calWrong dose
65 (9.0)
16 (2.4)
−73.3
< 0.01 b
culated creatinine clearance but did not flag
b
Wrong frequency
30 (4.2)
9 (1.4)
−66.7
< 0.01
incomplete regimens or errors in medication
Drug interaction
63 (8.7)
32 (4.8)
−44.8
< 0.01 b
dosing or scheduling.20 In another study, a
primarily pharmacy-driven resolution was
CCR5 errors
achieved through daily medication review,
Wrong dose
1 (0.1)
2 (0.3)
+200.0
0.61
superimposed on education, CPOE alerts,
Wrong frequency
0 (0.0)
0 (0.0)
0.0
1.00
and formulary conversions.22
With the goal of achieving optimal cliniDrug interaction
1 (0.1)
3 (0.5)
+400.0
0.35
cal outcomes related to antimicrobial use
Integrase inhibitor errors
and minimizing adverse drug events and the
potential for drug resistance, antimicrobial
Wrong dose
1 (0.1)
3 (0.5)
+400.0
0.35
stewardship is well positioned to intervene in
Wrong frequency
8 (1.1)
5 (0.8)
−27.3
0.58
the problem of ARV prescribing errors. This
Drug interaction
1 (0.1)
0 (0.0)
−100.0
1.00
approach was recently reported by Sander
a
et al., in which an intervention that included
Data presented as n (%)
b
Statistically significant
education, modification of electronic records,
collaboration with infectious disease (ID)
CCR5 = chemokine (C-C motif) receptor 5 inhibitor; NNRTI = nonnucleoside reverse-transcriptase
specialists, and prospective auditing by ID
inhibitor; NRTI = nucleos(t)ide reverse-transcriptase inhibitor; PI = protease inhibitor
clinical pharmacists of HIV-related medicaated with errors as a result of multiple available formulations,
tion orders resulted in a significantly higher (74% versus
the use of ritonavir for so-called boosted regimens, and inter35%) post-intervention error resolution rate.25 In our study,
actions with proton pump inhibitors, histamine receptor 2
the stewardship effort was further enhanced by the use of
blockers, and statins. This is consistent with findings from
COES superimposed on established educational tools and
this study that suggest PI-based regimens were independently
multidisciplinary communication between prescribers, ID
associated with ARV prescribing errors (Table 3). Possibly, the
specialists, and ID pharmacists.
decrease in concomitant use of potentially interacting drugs
CPOE systems have been observed to both reduce and
and prescribers’ increased familiarity with ritonavir’s use as a
facilitate medication errors.21,28 The potential for ordering
booster may have contributed to a reduction in PI-associated
errors is likely to be increased for unusual ARV regimens,
errors after the introduction of COES. The reduction in the
especially in the highly treatment-experienced patient with
percentage of PI-associated errors likely accounts for the
multiple genotypic resistance mutations, and with the ordering
increase in the proportion of NRTI errors.
of nonformulary ARVs. Therefore, to reduce such ordering
The prescribing of single-pill formulations such as efavirenz/
errors, COES must be constantly updated and HIV clinical
emtricitabine/tenofovir and emtricitabine/rilpivirine/tenofospecialists and pharmacists must be readily available.
vir (Complera, Gilead Sciences) among hospitalized patients
There are a number of potential limitations to this study. The
remained just over 10% between the two study periods. With
retrospective nature of the review may have allowed unreca decreased pill burden and potential for increased medicaognized bias. The study is based on data from a single large
tertiary-care teaching hospital in an urban setting; the results
tion adherence, these formulations can be expected to be
may not be applicable to all hospital settings. Multiple hospiprescribed more frequently. However, their use in persons
talizations per patient may have occurred during each study
with renal insufficiency will be limited. Errors associated with

Table 2 Prescribing Errors During Pre-Intervention and Post-Intervention
Periods Stratified by Pharmacological Class

358 P&T

®

• May 2015 • Vol. 40 No. 5

Customized Order-Entry Sets Can Prevent Antiretroviral Prescribing Errors
Table 3 Multivariate Logistic Regression Analysis of
Factors Associated With Antiretroviral Prescribing Errors
Variables

Adjusted OR
(95% CI)

P Values

Pre-intervention period

1.79 (1.39–2.31)

< 0.01*

African-American

0.96 (0.74–1.23)

0.73

Viral load > 40 copies/mL

0.79 (0.61–1.02)

0.07

PI-based ARV regimen

2.03 (1.53–2.70)

< 0.01*

Admitted to Internal Medicine

1.02 (0.77–1.36)

0.88

* Statistically significant
ARV = antiretroviral; OR = odds ratio; PI, protease inhibitor

period as well as during both study periods, but each admission
presented as an opportunity for ARV ordering. Patient characteristics (such as degree of renal insufficiency, comorbidities,
or reasons for hospitalization) before and after the introduction
of COES may have differed in unrecognized ways. The pattern
of ARV prescribing or prescriber characteristics may have
changed over time. Familiarity with ARVs and management
may have differed between the two periods studied. Possibly,
newer ARVs and formulations and increased ARV resistance
between the two populations studied may have confounded our
analysis of the impact of COES. We attempted to control for
possible seasonal effects on hospital admissions by reviewing
the same period of the year; we also intended that this would
control for the experience of medical residents, who comprise
a significant proportion of prescribers at our institution.
Although ARV medication errors cannot be prevented completely, health care providers must exercise caution when
prescribing ARVs. It is sobering to consider that ARV regimens
incorrectly prescribed for even brief periods could have both
short- and long-term consequences with adverse effects, viral
resistance, and clinical outcomes. A multifaceted approach
to error prevention under the auspices of an antimicrobial
stewardship program should include education with updated,
user-friendly tools to increase awareness, active real-time
auditing of ARV ordering, consultation with HIV ID specialists
or dedicated clinical pharmacists, and effective reconciliation of inpatient orders with outpatient records. Upon patient
discharge, it is also crucial to ensure that the patient will be
provided with prescriptions for the correct ARV regimens
during the transition in care.
In conclusion, COES can further prevent ARV prescribing
errors before they occur among hospitalized patients with HIV
infection in large urban areas with high HIV prevalence and
may prove to be a useful, stand-alone, and cost-efficient means
of reducing ARV prescribing errors in hospitals that do not
have HIV clinical specialists and pharmacists. Vigilance must
be maintained to keep the ordering system updated to ensure
correctness in prescribing, especially as newer medications
and formulations become available and drug interactions are
better described. Future studies might focus additionally on
the use of COES in other health care settings, such as longterm care facilities, clinics, ambulatory surgical centers, and
dialysis centers, and on the use of medications for primary and
secondary prophylaxis of opportunistic infections.
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